1-20 of 149
chymotrypsin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Fazal Shirazi, PhD, Richard J. Jones, PhD, Isere Kuiatse, PhD, Zuzana Berkova, PhD, Hua Wang, PhD, Hans C. Lee, MD, Samuel Hong, PhD, Ram Kumar Singh, PhD, Lawrence Robert Dick, PhD, Nibedita Chattopadhyay, PhD, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 406.
https://doi.org/10.1182/blood-2018-99-117577
Published: 2018
Journal Articles

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Parameswaran Hari, MBBS, MD, Mark A. Schroeder, MD, James R Berenson, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Peter M. Voorhees, MD, Hisaki Fujii, Zhao Yang, Francesco Galimi, MDPhD, Kenneth H. Shain, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 803.
https://doi.org/10.1182/blood-2018-99-112610
Published: 2018
Journal Articles

Development of Novel Proteasome-HDAC6 Hybrid Inhibitors for Resistant ALL Phenotype

Sanil Bhatia, PhD, Nina Ressing, Alexandra Herrlich, Arndt Borkhardt, Prof MD, Finn Hansen, JProf. Dr., Julia Hauer, Prof. Dr.
Journal: Blood
Blood (2017) 130 (Supplement 1): 2070.
https://doi.org/10.1182/blood.V130.Suppl_1.2070.2070
Published: 2017
Journal Articles

Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Eleni-Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Evangelia Chavdoula, Efstathios Iliodromitis, Apostolos Klinakis, Meletios A. Dimopoulos, Ioanna Andreadou, Evangelos Terpos, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3086.
https://doi.org/10.1182/blood.V130.Suppl_1.3086.3086
Published: 2017
Journal Articles

Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study

Heinz Ludwig, MD, Andrew Spencer, MD, Tibor Kovacsovics, Nashat Y. Gabrail, Leonard Minuk, Amy S. Kimball, Robert J. Pelham, Ying C. Ou, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3125.
https://doi.org/10.1182/blood.V130.Suppl_1.3125.3125
Published: 2017
Journal Articles

Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study

Benjamin Ole Wolthers, MD, Thomas Leth Frandsen, MD PhD, Andishe Attarbaschi, MD, Shlomit Barzilai, MD, Antonella Colombini, Gabriele Escherich, MD, Marie Grosjean, Ramneek Gupta, PhD, Der-Cherng Liang, MD, Anja Moricke, MD, Chirag J Patel, PhD, Kirsten K Rasmussen, Sujith Samarasinghe, Inge M. Van Der Sluis, MD PhD, Martin Stanulla, MD PhD, Morten Tulstrup, MD, Ester Zapotocka, MD, Kjeld Schmiegelow, MD DMSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 885.
https://doi.org/10.1182/blood.V130.Suppl_1.885.885
Published: 2017
Journal Articles

Hemopoietic Progenitor Cells from the Bone Marrow of Serpinb3A-/- Mice Are Radioresistant

Stephanie Thermozier, Michael W. Epperly, PhD, Darcy Franicola, Xichen Zhang, Renee Fisher, Donna Shields, Hong Wang, John A. Willis, Cliff Luke, Gary A. Silverman, Joel S. Greenberger, MD
Journal: Blood
Blood (2016) 128 (22): 2680.
https://doi.org/10.1182/blood.V128.22.2680.2680
Published: 2016
Journal Articles

Proteasome and HDAC Inhibitor Therapy in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Nuclear Factor Erythroid 2 like 2 (NRF2)-Dependent Cell Death and Function

Frank C. Passero, Jr., MD, Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, J. Tyson McDonald, PhD, Andrew M Evens, DO, MSc, FACP
Journal: Blood
Blood (2016) 128 (22): 3020.
https://doi.org/10.1182/blood.V128.22.3020.3020
Published: 2016
Journal Articles

Fate of Ikaros in Multiple Myeloma Cells upon Treatment with Lenalidomide and Proteasome Inhibitor

Saravanan Ganesan, MSc, Nithya Balasundaram, MSc, Hamenth Kumar Palani, MSc, Ansu Abu Alex, MSc, Sachin David, MSc, Anup Joseph Devasia, MD DM, Biju George, MD DM, Poonkuzhali Balasubramanian, MSc PhD, Vikram Mathews, MD DM
Journal: Blood
Blood (2016) 128 (22): 3281.
https://doi.org/10.1182/blood.V128.22.3281.3281
Published: 2016
Journal Articles

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

Andrew Spencer, Simon Harrison, MBBS MRCP(UK) FRCPath(UK) FRACP PhD, Jacob P. Laubach, MD, Jeffrey Zonder, MD, Ashraf Z Badros, MD, Krystal Bergin, Amit Khot, MD, Todd Zimmerman, MD, Kenneth C. Anderson, MD, Ann MacLaren, PhD, Steven D Reich, MD, Mohit Trikha, PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2016) 128 (22): 3326.
https://doi.org/10.1182/blood.V128.22.3326.3326
Published: 2016
Journal Articles

Novel Sites of Gamma Carboxylation in Human Factor VII

Emily M Wilkerson, Barbara Bates, Kraig T Kumfer, Nicholas M Riley, Brad S Schwartz, Joshua J Coon
Journal: Blood
Blood (2016) 128 (22): 3759.
https://doi.org/10.1182/blood.V128.22.3759.3759
Published: 2016
Journal Articles

Targeted Inhibition of Activated Protein C Anticoagulant Activity By Monoclonal Antibody HAPC1573 for Treatment of Hemophilia

Xiao-Yan Zhao, PhD, Subramanian Yegneswaran, PhD, Maxine Bauzon, Derek Sim, Chandra Patel, PhD, Doug Schneider, Kirk McLean, Ying Zhu, MD, Xiaoqiao Jiang, Vince Evans, Jian-Ming Gu, PhD, Inge Ivens, PhD, Jun Xu, PhD, Peter Wolfgang Bringmann, PhD, Katalin Kauser, Charles Esmon, PhD
Journal: Blood
Blood (2016) 128 (22): 80.
https://doi.org/10.1182/blood.V128.22.80.80
Published: 2016
Journal Articles

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4527.
https://doi.org/10.1182/blood.V128.22.4527.4527
Published: 2016
Journal Articles

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Daniël Verhoef, Mark Schreuder, Ka Lei Cheung, Pieter H. Reitsma, Mettine H.A. Bos, PhD
Journal: Blood
Blood (2015) 126 (23): 126.
https://doi.org/10.1182/blood.V126.23.126.126
Published: 2015
Journal Articles

Analysis of the Glycan Composition on Plasma Derived ADAMTS13 Employing Tandem Mass Spectrometry

Fabian Verbij, MSc, Eva Stokhuijzen, MSc, Floris van Alphen, Paul Kaijen, Alexander Meijer, PhD, Jan Voorberg, PhD
Journal: Blood
Blood (2015) 126 (23): 1069.
https://doi.org/10.1182/blood.V126.23.1069.1069
Published: 2015
Journal Articles

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)

James Berenson, MD, Alan Cartmell, Roger Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph V. Boccia, MD, Morton Coleman, Robert A. Moss, MD, Robert M. Rifkin, Marco Schupp, Sandra Dixon, Ying Ou, Janet Anderl, Jesus G. Berdeja, MD
Journal: Blood
Blood (2015) 126 (23): 373.
https://doi.org/10.1182/blood.V126.23.373.373
Published: 2015
Journal Articles

Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans

Eleni-Dimitra Papanagnou, Tina Bagratuni, Efstathios Kastritis, Issidora Papassideri, Evangelos Terpos, MD, Meletios A. Dimopoulos, Ioannis P. Trougakos
Journal: Blood
Blood (2015) 126 (23): 3250.
https://doi.org/10.1182/blood.V126.23.3250.3250
Published: 2015
Journal Articles

Crispr Sgrnas Genome-Wide Screen Identifies the Proteasome Regulatory Subunit PSMC6 As a Bortezomib Resistance Gene in Human Multiple Myeloma Cells

Chang-Xin Shi, PhD, Klaus M Kortum, MD, Yuan Xiao Zhu, PhD, Patrick Jedlowski, Esteban Braggio, PhD, Laura Ann Bruins, Patrick G. Votruba, M.S., Moulun Luo, PhD, Robert A. Stewart, Jonathan M. Ahmann, A. Keith Stewart
Journal: Blood
Blood (2015) 126 (23): 450.
https://doi.org/10.1182/blood.V126.23.450.450
Published: 2015
Journal Articles

Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma

Andrew Spencer, Jacob P. Laubach, MD, Jeffrey A Zonder, MD, Ashraf Z Badros, MD, Simon Harrison, MD, Amit Khot, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Steven D Reich, MD, Mohit Trikha, PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 4220.
https://doi.org/10.1182/blood.V126.23.4220.4220
Published: 2015
Journal Articles

Identification of the Protein S Binding Site in the Factor IXa Serine Protease Domain Presents Therapeutic Possibilities

William E. Plautz, Satish Sekhar, Rinku Majumder, PhD, John P. Sheehan, MD
Journal: Blood
Blood (2015) 126 (23): 2274.
https://doi.org/10.1182/blood.V126.23.2274.2274
Published: 2015